StockNews.AI
NMRA
StockNews.AI
152 days

Neumora Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA

1. A class action lawsuit has been filed against Neumora Therapeutics, Inc. (NMRA). 2. Allegations include misleading statements regarding clinical trial participant criteria. 3. Shareholders who purchased NMRA stock during the class period are encouraged to register. 4. The lawsuit may hinder investor confidence and affect NMRA stock price. 5. The deadline for lead plaintiff registration is April 7, 2025.

6m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit can create uncertainty and negative sentiment around NMRA, similar to past cases where similar allegations led to stock declines for affected companies.

How important is it?

The lawsuit indicates fundamental issues with disclosures and trial data that could seriously impact NMRA's credibility and stock valuation.

Why Long Term?

The implications of ongoing litigation could affect NMRA's market perception and stock performance long-term, as seen in other biotech firms facing legal challenges.

Related Companies

VRTXBIOCPTGX
, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=137072&from=4 CLASS PERIOD: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023. ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora's flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. DEADLINE: April 7, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=137072&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NMRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: (646) 453-8903 SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In Also from this source

Related News